Trends In TBI Biomarker Discovery And Commercialization

Report Overview

Traumatic brain injury (TBI) is a major global health concern, particularly affecting children and young adults, and stands as a leading cause of death and long-term disability. Globally, more than 50 million TBIs occur each year, with an estimated economic burden exceeding $400 billion. While advances in clinical care and research have improved our understanding of TBI, there is still a pressing need for more reliable diagnostic and prognostic tools.

The identification and validation of biomarkers spanning genomics, proteomics, and neuroimaging are critical to addressing the complex and heterogeneous nature of TBI and advancing toward precision medicine. This heterogeneity poses significant obstacles in biomarker discovery, validation, and clinical integration. To enhance the success of biomarker development and implementation, researchers must confront variability in data collection, apply stringent data reduction techniques, and conduct thorough statistical analysis and validation.

TBIs, including concussions, are widespread and not limited to sports-related injuries. Each year, approximately 4.8 million emergency room visits in the U.S. are attributed to TBIs, with nearly 40% of concussions resulting from slips and falls.

The trends and competitive analysis report, compiled by Grand View Research, is a collection of the trends and competitive scenario in more than 20 countries. Qualitative information regarding the trends, government initiatives, funding landscape, competitive strategies, existing competition, and pipeline analysis will be provided in the report. Within the purview of the database, such information is systematically analyzed and provided in the form of outlook reports and summary presentations on individual areas of research.

Trends In TBI Biomarker Discovery And Commercialization Report Scope

Trends In TBI Biomarker Discovery And Commercialization Analysis Coverage Snapshot

Challenges In TBI Diagnosis

Traumatic brain injuries (TBIs), including concussions, often go undiagnosed or are misdiagnosed due to reliance on subjective assessments like CT scans, patient interviews, and neurological exam methods that lack empirical precision when used alone. Given the potential for both immediate and long-term consequences, the need for objective, rapid, and accurate diagnostic tools is critical.

Case Study: i-STAT Alinity - A Game-Changing Diagnostic Tool

In response to the historical and ongoing challenges of combat-related TBIs, researchers, co-founders of Banyan Biomarkers, Inc., developed a protein-based platform for TBI detection. Initial development was supported by the Peer Reviewed Medical Research Program and the Traumatic Brain Injury and Psychological Health Research Program.

Originally developed to analyze plasma, the test required additional steps like centrifugation, making it impractical in the field or low-resource settings. This limitation was overcome with the introduction of the i-STAT TBI cartridge, which works with whole blood and delivers lab-quality results in just 15 minutes using Abbott’s handheld i-STAT Alinity device.

“The i-STAT TBI cartridge is a game changer... it no longer requires the extra step of centrifugation”

This simplified method enables testing in operational or remote environments, offering rapid triage for military personnel and potentially civilians. The test helps determine whether a CT scan is necessary, thereby reducing unnecessary imaging and streamlining care.

The success of the pivotal ALERT-TBI trial (~2,000 participants) validated the test’s ability to identify CT-scan-detectable brain injuries within 12 hours of injury. 

Market Impact & Future Outlook

Abbott’s Alinity i test represents more than just a diagnostic tool; it may signal the beginning of a new phase in TBI evaluation. With large EMR datasets and biomarker data integration, researchers can now explore mild TBI and post-concussion syndrome in ways that were previously not possible.

The shift from traditional tools to biofluid-based, point-of-care diagnostics has the potential to:

• Reduce unnecessary imaging

• Improve triage and treatment accuracy

• Personalize recovery plans

• Enable scalable use across civilian, athletic, and military populations.

FUNDING PROGRAMS TO PROMOTE THE TBI RESEARCH

• In March 2024, the Barrow Neurological Institute received an R21 grant from the NIH for a pioneering study focused on predicting and preventing contusion expansion in traumatic brain injury (TBI). Contusion expansion, involving increased swelling and bleeding, significantly raises the risk of death and disability. Despite its severity, current treatments remain largely unchanged. The study, led by Dr. Jha and collaborators from the University of Pittsburgh, explores the SUR1-TRPM4 ion channel, which responds to brain injury and contributes to swelling and bleeding. Identifying biomarkers linked to this channel could enable more precise, targeted therapies for TBI.

• In November 2023, Penn Medicine researchers received an $8 million grant from the Department of Defense to advance research into biomarkers for traumatic brain injury (TBI). Led by Douglas H. Smith, MD, and Ramon Diaz-Arrastia, MD, PhD, the research will focus on identifying biomarkers to characterize the evolving endophenotypes of degeneration after TBI. This work will be carried out by the Center for Brain Injury and Repair (CBIR) at the Perelman School of Medicine, with the aim of testing new TBI treatments in future clinical trials.

In addition to government initiatives, strategic activities by key market players and the launch of technologically advanced products will create lucrative opportunities.